[Redefining treatment of rheumatic arthritis with anti-cytokines]

[Article in French]

Editorial

[Article in French]

C Gabay et al. Rev Med Suisse. 2007.

. 2007 Mar 21;3(103):715-7.

No abstract available

Similar articles

Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Redlich K, et al. Arthritis Rheum. 2003 Dec;48(12):3308-19. doi: 10.1002/art.11358. Arthritis Rheum. 2003. PMID: 14673982 Review. No abstract available.
The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
Kavanaugh A, Cohen S, Cush JJ. Kavanaugh A, et al. J Rheumatol. 2004 Oct;31(10):1881-4. J Rheumatol. 2004. PMID: 15468347 No abstract available.
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?
Bobbio-Pallavicini F, Caporali R, Bugatti S, Montecucco C. Bobbio-Pallavicini F, et al. J Rheumatol. 2008 Oct;35(10):1903-5. J Rheumatol. 2008. PMID: 18843754 No abstract available.
Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
Saxne T, Larsson L, Geborek P. Saxne T, et al. Arthritis Rheum. 2004 Sep;50(9):3049-50; author reply 3050-1. doi: 10.1002/art.20640. Arthritis Rheum. 2004. PMID: 15457477 No abstract available.
How antirheumatic drugs protect joints from damage in rheumatoid arthritis.
Schett G, Stach C, Zwerina J, Voll R, Manger B. Schett G, et al. Arthritis Rheum. 2008 Oct;58(10):2936-48. doi: 10.1002/art.23951. Arthritis Rheum. 2008. PMID: 18821703 Review. No abstract available.